• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Linda Stein Gold on What to Look Forward to at AAD 2022

Video

Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.

Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.

Transcript

What are you most looking forward to at the 2022 American Academy of Dermatology Annual Meeting?

I'm looking forward to a lot of things at AAD 2022. First of all, I'm looking forward to seeing my colleagues in person and catching up. And I'm also looking forward to really getting educated on the latest data in medical, pediatric, and cosmetic dermatology.

What can attendees expect to learn at AAD 2022?

The meeting is going to be very comprehensive, with updates in all areas of dermatology. I personally will be chairing the acne and rosacea symposium and I'll begin giving an update on what's new in topical therapy. I'll be giving some updates on what's new in acne and rosacea in general. I'll also be talking about some of the latest breakthroughs in topical therapy for psoriasis and, in one interesting session, I'll be talking about the challenges of conducting clinical trials, and specifically the challenge of patient recruiting.

What are some of the big issues in dermatology that you hope to see addressed?

There are a lot of issues in dermatology right now and Academy leadership has so much on their plates, but I think they've been doing a really good job in tackling some of our main issues. Some of these include scope of practice battles, the cost of both treating and not treating our patients, the 2022 changes in MIPS [Merit-based Incentive Payment System] and MACRA [Medicare Access and CHIP Reauthorization Act], and also helping us to restore faith in iPLEDGE [Risk Evaluation and Mitigation Strategy program]. We're also making a major push for DEI [diversity, equity, and inclusion].

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Sandra Cueller, PharmD
Ticiana Leal, MD
James Chambers, PhD
Mabel Mardones, MD.
Dr Bonnie Qin
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.